GSK and Vir to expand Covid-19 antibody treatment study
Phase III study will be conducted on around 1,300 non-hospitalised patients globally. Credit: Thor Deichmann from Pixabay.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more